Hangzhou Jiuyuan Genetic Biopharmaceutical (02566) Announces Share Repurchase and Updated Shareholding Structure

Bulletin Express

Feb 10

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed that on 10 February 2026, 285,200 H shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 9.83 to HKD 10.3, for an aggregate consideration of approximately HKD 2.87 million. Following this transaction, the total number of shares stood at 109,096,785, comprising 105,248,985 issued shares (excluding treasury shares) and 3,847,800 treasury shares.

The repurchase falls under a mandate authorized on 11 June 2025, permitting the company to repurchase up to 10,909,678 shares. As of the latest disclosure, 3,847,800 shares have been repurchased under this mandate, representing approximately 3.52696% of the total number of issued shares (excluding treasury shares) on the date the mandate was granted. A moratorium on new share issuance or treasury share sales remains in effect until 12 March 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141108502"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141108502\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141108502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141108502","market":"us","top_or_hot":-1,"title":"Hangzhou Jiuyuan Genetic Biopharmaceutical (02566) Announces Share Repurchase and Updated Shareholding Structure","media":"Bulletin Express","content":"<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed that on 10 February 2026, 285,200 H shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 9.83 to HKD 10.3, for an aggregate consideration of approximately HKD 2.87 million. Following this transaction, the total number of shares stood at 109,096,785, comprising 105,248,985 issued shares (excluding treasury shares) and 3,847,800 treasury shares.</p>\n<p>The repurchase falls under a mandate authorized on 11 June 2025, permitting the company to repurchase up to 10,909,678 shares. As of the latest disclosure, 3,847,800 shares have been repurchased under this mandate, representing approximately 3.52696% of the total number of issued shares (excluding treasury shares) on the date the mandate was granted. A moratorium on new share issuance or treasury share sales remains in effect until 12 March 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Jiuyuan Genetic Biopharmaceutical (02566) Announces Share Repurchase and Updated Shareholding Structure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Jiuyuan Genetic Biopharmaceutical (02566) Announces Share Repurchase and Updated Shareholding Structure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-10 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed that on 10 February 2026, 285,200 H shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 9.83 to HKD 10.3, for an aggregate consideration of approximately HKD 2.87 million. Following this transaction, the total number of shares stood at 109,096,785, comprising 105,248,985 issued shares (excluding treasury shares) and 3,847,800 treasury shares.</p>\n<p>The repurchase falls under a mandate authorized on 11 June 2025, permitting the company to repurchase up to 10,909,678 shares. As of the latest disclosure, 3,847,800 shares have been repurchased under this mandate, representing approximately 3.52696% of the total number of issued shares (excluding treasury shares) on the date the mandate was granted. A moratorium on new share issuance or treasury share sales remains in effect until 12 March 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1141108502","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141108502","pubTimestamp":1770721339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed that on 10 February 2026, 285,200 H shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 9.83 to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"杭州九元基因生物制药(02566)公布购回股份及更新股权架构","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed that on 10 February 2026, 285,200 H shares were repurchased on the Hong Kong Stock Exchange at prices ranging from HKD 9.83 to HKD 10.3, for an aggregate consideration of approximately HKD 2.87 million. Following this transaction, the total number of shares stood at 109,096,785, comprising 105,248,985 issued shares (excluding treasury shares) and 3,847,800 treasury shares.\nThe repurchase falls under a mandate authorized on 11 June 2025, permitting the company to repurchase up to 10,909,678 shares. As of the latest disclosure, 3,847,800 shares have been repurchased under this mandate, representing approximately 3.52696% of the total number of issued shares (excluding treasury shares) on the date the mandate was granted. A moratorium on new share issuance or treasury share sales remains in effect until 12 March 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}